Palatin Technologies, Inc. (PTN) stock surged +0.82%, trading at $16.05 on AMEX, up from the previous close of $15.92. The stock opened at $15.01, fluctuating between $14.89 and $16.05 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Feb 05, 2026 | 16.21 | 16.21 | 14.75 | 16.05 | 21.92K |
| Feb 04, 2026 | 17.28 | 17.28 | 15.10 | 15.92 | 31.65K |
| Feb 03, 2026 | 16.64 | 17.40 | 16.16 | 17.35 | 49.12K |
| Feb 02, 2026 | 14.48 | 17.40 | 14.48 | 17.25 | 32.71K |
| Jan 30, 2026 | 14.98 | 15.85 | 14.71 | 14.71 | 21.59K |
| Jan 29, 2026 | 16.33 | 17.45 | 14.97 | 14.97 | 43.79K |
| Jan 28, 2026 | 15.64 | 16.95 | 15.64 | 16.95 | 14.28K |
| Jan 27, 2026 | 16.19 | 16.43 | 15.25 | 16.22 | 18.3K |
| Jan 26, 2026 | 17.25 | 17.25 | 15.44 | 16.32 | 18.61K |
| Jan 23, 2026 | 17.35 | 18.40 | 15.97 | 16.60 | 17.07K |
| Jan 22, 2026 | 16.23 | 18.49 | 16.23 | 16.70 | 36.01K |
| Jan 21, 2026 | 16.15 | 17.99 | 15.88 | 16.31 | 27.49K |
| Jan 20, 2026 | 18.79 | 18.79 | 15.57 | 16.81 | 20.28K |
| Jan 16, 2026 | 15.75 | 19.16 | 15.75 | 17.55 | 39.54K |
| Jan 15, 2026 | 17.00 | 17.26 | 16.26 | 16.93 | 32.42K |
| Jan 14, 2026 | 16.61 | 16.99 | 15.00 | 16.81 | 53.81K |
| Jan 13, 2026 | 14.70 | 18.00 | 14.25 | 17.20 | 59.2K |
| Jan 12, 2026 | 16.05 | 16.05 | 14.30 | 14.69 | 32.24K |
| Jan 09, 2026 | 17.25 | 17.93 | 15.06 | 15.51 | 33.51K |
| Jan 08, 2026 | 17.48 | 17.75 | 16.93 | 17.02 | 28.39K |
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
| Employees | 30 |
| Beta | 0.94 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | -1% |
| Fiscal Year Ends | June |
| Sector | Healthcare |
| Industry | Biotechnology |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep